Kineta Enters Into $5 Million Agreement With TuHURA Biosciences for Vista Blocking Immunotherapy; Shares Rise

MT Newswires Live07-08

Kineta (KA) said Monday it has entered into an exclusivity and right of first offer agreement with TuHURA Biosciences, granting the oncology company an exclusive right to buy its worldwide patents, patent rights, patent applications, product and development program assets and other rights and assets linked to its Vista blocking immunotherapy program, KVA12123, for a nonrefundable payment of $5 million.

VISTA blocking monoclonal antibody is currently being evaluated in a phase 1/phase 2 clinical trial for patients with advanced solid tumors.

The exclusive right will continue either to the execution of any definitive agreement with TuHURA or by Oct. 1, subject to extension, Kineta said.

Kineta shares were nearly 20% higher in premarket trading.

Price: 0.7229, Change: +0.12, Percent Change: +19.13

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2449779390?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-08 19:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2449779390","market":"sg","top_or_hot":-1,"title":"Kineta Enters Into $5 Million Agreement With TuHURA Biosciences for Vista Blocking Immunotherapy; Shares Rise","media":"MT Newswires Live","content":"<html><body><p> Kineta (KA) said Monday it has entered into an exclusivity and right of first offer agreement with TuHURA Biosciences, granting the oncology company an exclusive right to buy its worldwide patents, patent rights, patent applications, product and development program assets and other rights and assets linked to its Vista blocking immunotherapy program, KVA12123, for a nonrefundable payment of $5 million.</p><p>VISTA blocking monoclonal antibody is currently being evaluated in a phase 1/phase 2 clinical trial for patients with advanced solid tumors.</p><p>The exclusive right will continue either to the execution of any definitive agreement with TuHURA or by Oct. 1, subject to extension, Kineta said.</p><p>Kineta shares were nearly 20% higher in premarket trading.</p><p>Price: 0.7229, Change: +0.12, Percent Change: +19.13</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kineta Enters Into $5 Million Agreement With TuHURA Biosciences for Vista Blocking Immunotherapy; Shares Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKineta Enters Into $5 Million Agreement With TuHURA Biosciences for Vista Blocking Immunotherapy; Shares Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-08 19:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kineta (KA) said Monday it has entered into an exclusivity and right of first offer agreement with TuHURA Biosciences, granting the oncology company an exclusive right to buy its worldwide patents, ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VGZ","symbol_name":"Vista Gold Corp","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2449779390","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2449779390","pubTimestamp":1720438671,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Kineta  said Monday it has entered into an exclusivity and right of first offer agreement with TuHURA Biosciences, granting the oncology company an exclusive right to buy its worldwide patents, patent rights, patent applications, product and development program assets and other rights and assets linked to its Vista blocking immunotherapy program, KVA12123, for a nonrefundable payment of $5 million.VISTA blocking monoclonal antibody is currently being evaluated in a phase 1/phase 2 clinical trial for patients with advanced solid tumors.The exclusive right will continue either to the execution of any definitive agreement with TuHURA or by Oct. 1, subject to extension, Kineta said.Kineta shares were nearly 20% higher in premarket trading.Price: 0.7229, Change: +0.12, Percent Change: +19.13","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VGZ":"Vista Gold Corp","KA":"Kineta Inc.","BK4017":"黄金","BK4139":"生物科技"},"translate_title":"Kineta与TuHURA Biosciences签订价值500万美元的Vista阻断免疫疗法协议；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VGZ":1,"KA":0.9},"content_text":"Kineta (KA) said Monday it has entered into an exclusivity and right of first offer agreement with TuHURA Biosciences, granting the oncology company an exclusive right to buy its worldwide patents, patent rights, patent applications, product and development program assets and other rights and assets linked to its Vista blocking immunotherapy program, KVA12123, for a nonrefundable payment of $5 million.VISTA blocking monoclonal antibody is currently being evaluated in a phase 1/phase 2 clinical trial for patients with advanced solid tumors.The exclusive right will continue either to the execution of any definitive agreement with TuHURA or by Oct. 1, subject to extension, Kineta said.Kineta shares were nearly 20% higher in premarket trading.Price: 0.7229, Change: +0.12, Percent Change: +19.13","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2449779390"}